Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Crosses Below 50 Day Moving Average - Here's Why

Tarsus Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Tarsus shares fell below their 50-day moving average, trading as low as $72.57 and last at $73.01, versus the average of $74.09; the stock was reported down 6%.
  • Its latest quarterly results showed an EPS loss of $14.40, missing consensus estimates of a $1.46 loss, while revenue of $194.57 million exceeded expectations of $187.83 million.
  • Analyst sentiment remains broadly positive: MarketBeat’s consensus is “Moderate Buy”, with a $104.57 average price target, despite a mix of ratings and recent insider share sales.
  • MarketBeat previews top five stocks to own in December.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $74.09 and traded as low as $72.57. Tarsus Pharmaceuticals shares last traded at $73.01, with a volume of 706,752 shares.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TARS. Mizuho dropped their target price on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating on the stock in a report on Friday, July 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, October 15th. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, August 12th. Zacks Research raised shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 13th. Finally, Barclays assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They issued an "overweight" rating and a $110.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $104.57.

Get Our Latest Report on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Trading Down 6.0%

The company has a 50 day moving average of $74.09 and a two-hundred day moving average of $68.26. The stock has a market capitalization of $3.60 billion, a PE ratio of -4.81 and a beta of 0.34. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.94 and a current ratio of 1.96.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($14.40) EPS for the quarter, missing analysts' consensus estimates of ($1.46) by ($12.94). The business had revenue of $194.57 million during the quarter, compared to analysts' expectations of $187.83 million. Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%. Sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -15.64 EPS for the current year.

Insider Activity

In other news, Director William Link, PhD sold 12,500 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the transaction, the director owned 94,487 shares in the company, valued at $7,405,891.06. This represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 10,773 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $942,637.50. Following the completion of the transaction, the insider directly owned 2,547 shares of the company's stock, valued at $222,862.50. The trade was a 80.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 58,031 shares of company stock worth $4,807,327 over the last 90 days. 9.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth $35,000. Parallel Advisors LLC grew its holdings in shares of Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock valued at $35,000 after buying an additional 291 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Tarsus Pharmaceuticals by 851.6% during the third quarter. Farther Finance Advisors LLC now owns 590 shares of the company's stock valued at $46,000 after buying an additional 528 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock valued at $50,000 after acquiring an additional 558 shares during the period. Finally, Covestor Ltd increased its position in shares of Tarsus Pharmaceuticals by 40.0% in the 3rd quarter. Covestor Ltd now owns 1,095 shares of the company's stock valued at $86,000 after acquiring an additional 313 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company's work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions. Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?

Before you consider Tarsus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.

While Tarsus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines